AstraZeneca Buys Second Amgen Biologics Manufacturing Facility
By

By
AstraZeneca has purchased a second biologics manufacturing facility in Longmont, Colorado from Amgen that will be used to support AstraZeneca’s existing operations at its nearby Boulder, Colorado site. AstraZeneca first…

BI Divests Animal Health Assets in Sanofi Business Swap
By

By
Boehringer Ingelheim (BI) has entered into an agreement with Ceva Santé Animale, an animal-health company headquartered in Libourne, France, under which Ceva will purchase certain portfolio assets of Merial, Sanofi’s…

Cambrex Opens New API Pilot Plant
By

By
Cambrex has opened its new active pharmaceutical ingredient (API) pilot plant in Milan, Italy, following validation and ISO certification. The cGMP plant, which can produce batch sizes from 1 kilogram…

WuXi AppTec Opens New Biomanufacturing Facility
By

By
WuXi AppTec, a contract provider of drug discovery and development services, has opened a new 150,000-square-foot biomanufacturing facility for cell and gene therapies in Philadelphia. The facility is designed for…

Parexel Launches Tracking Service for Temperature-Controlled Medicines
By

By
Parexel International, a Waltham, Massachusetts-based contract research organization, has launched an active tracking service that provides near real-time temperature and location monitoring of investigational medicinal products from central distribution centers to…

Alcami Introduces Back-up Supply Program
By

By
Alcami, a provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, has introduced Protect Your Brand, its program for implementing a back-up supply option. Under this…

US Gov’t Grants NewLink Genetics $25 Million to Develop Merck’s Ebola Vaccine
By

By
The Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services (HHS) has issued a $24.8 million contract to a subsidiary of NewLink Genetics Corporation,…

Kymab, EpimAb Biotherapeutics Partner to Develop Bispecific Antibodies
By

By
Kymab, a Cambridge, UK-based biopharmaceutical company focused on human monoclonal antibodies, has entered into a cross-licensing and development agreement with EpimAb Biotherapeutics, a Shanghai, China-based biopharmaceutical company focused on bispecific…

Nordic Nanovector, LegoChem Biosciences in Pact for Antibody-Drug Conjugates
By

By
Nordic Nanovector, an Oslo, Norway-based biopharmaceutical company focused on antibody radionuclide conjugates, has formed a collaboration with LegoChem Biosciences, a Daejeon, South Korea-based biopharmaceutical company, to develop CD37-targeting antibody-drug conjugates…

Shire Gains Favorable Ruling on US Patent for Ulcerative Colitis Drug
By

By
Shire has received a favorable ruling from the US Patent & Trademark Office’s Patent Trial and Appeal Board (PTAB), which issued their decision upholding the validity of US Patent No.…